Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
Myriad Genetics, Inc. Financials Banner

Myriad Genetics, Inc. Financials

MYGN Stock Analysis

Page title

Section title

MYGN Income Statement Key Metrics

  • Revenue(TTM)734.40 M
  • Gross Profit(TTM)505.90 M
  • EBITDA(TTM)-212.40 M
  • Net Income(TTM)-274.40 M
  • EPS Diluted(TTM)-3.36

Decode MYGN's Latest Earnings Call with Ease

Tap 'Generate' for a crystal-clear,
AI-crafted summary and stay ahead in the investment game!

MYGN earnings and revenue history

MYGN Return on Equity

See how efficiently MYGN generates profit for it's shareholders.

0%

10
0
100
  1. Poor

  2. Average

  3. Strong

Return on Equity Growth

MYGN's Return on Equity has shown poor growth over the past 10 years, increasing by only 6.40%.

MYGN Revenue Growth

See how MYGN has grown it's revenue over the past 10 years.


Revenue Growth

MYGN's revenue has shown poor growth over the past 10 years, increasing by only -1.36%.

MYGN FY, 2022 Revenue Breakdown

See how MYGN converts it's revenue into profit.

MYGN Balance Sheet Health

MYGN Balance Sheet Breakdown 2022

Assets

  1. Long Term Assets

  2. Cash & Equivalents

  3. Inventory

  4. Receivables

  5. Property Plant Equipments

  6. Others

Liabilities

  1. Short Term Debt

  2. Long Term Debt

  3. Account Payables

  4. Others

MYGN financial position analysis

Short Term Liabilities

MYGN's short term assets($275M) can safely cover it's short term liabilities($137M).

Long Term Liabilities

MYGN's short term assets($275M) can safely cover it's long term liabilities($176M).

MYGN Debt to Equity